Full-Time

Associate Director

CVRM Access Strategy

Posted on 4/29/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior

Wilmington, DE, USA

Relocation assistance is not available for this position.

Category
Strategy Development
Business Development
Business & Strategy
Required Skills
Market Research
Requirements
  • Bachelor's Degree required; preferably in business, marketing or the sciences
  • 5+ years of progressive experience within the pharmaceutical / biopharmaceutical market in any of the following areas: Payer Marketing, Brand Marketing, Market Research, Market Access, Account Management, and / or Field Sales
  • Understanding of the US market access landscape and the legal / regulatory environment for pharmaceuticals / biopharmaceuticals
  • Understanding of customer and industry marketing practices and trends
  • Willingness to travel domestically and internationally, if required
Responsibilities
  • Responsible for collaborating with cross-functional team (Marketing, Insights, Medical Affairs, Contract Strategy, and Field Integrators) as well as Market Access customer-facing teams to identify rich market insights across patients, providers, and payers to inform comprehensive market access strategies and aligned messaging across segments
  • Develops compelling and differentiated product value propositions and builds associated customer education materials
  • Partners with Contracting Strategy to develop effective contracting offerings that achieve access and contribution goals
  • Collaborates with the HCP / Marketing team on customer communication strategies and promotional assets
  • Effectively manages agency relationships ensuring promotional programs are delivered on-time and within budget
  • Develops and manages associated budgets in compliance with AZ finance and accounting requirements
  • Performs all company business in accordance with regulations and company policies and procedures
Desired Qualifications
  • MBA in relevant field
  • Experience developing and driving strategy
  • Managed care / payer experience
  • Ability to think strategically and to translate strategy into tactical implementation and to motivate people to execute on strategy
  • Teamwork and leadership skills, including the ability to gain consensus and act within ambiguous, complex matrix organization
  • Results oriented with excellent communication and collaboration skills
  • Demonstrated Learning Agility

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by rigorous clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by providing effective treatments for serious diseases while collaborating with the scientific community to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • New manufacturing facilities boost AstraZeneca's production capacity and supply chain resilience.
  • AstraZeneca's robust oncology pipeline reinforces its leadership in cancer care.
  • Strategic leadership moves may enhance research and development capabilities.

What critics are saying

  • Increased competition in oncology may impact AstraZeneca's market share.
  • Stricter regulatory scrutiny could delay drug approval processes.
  • Rising raw material costs may affect production costs and profit margins.

What makes AstraZeneca unique

  • AstraZeneca's AI collaboration enhances drug discovery efficiency and accuracy.
  • The EsoBiotec acquisition positions AstraZeneca as a leader in innovative cell therapies.
  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Silicon Canals
May 22nd, 2025
Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms

Aptar Digital Health announces licensing agreement with AstraZeneca to develop ai-powered screening algorithms.

HC Data
May 21st, 2025
AstraZeneca Marks Seventh Consecutive Year of Plenary Data at ASCO, Advancing Breast and Gastric Cancer Care

AstraZeneca will present new data from over 80 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3), underscoring its leadership in oncology through a diverse and robust pipeline.

Cision
May 21st, 2025
Director Declaration

21 May 2025Director DeclarationAstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed a director of Agilent Technologies Inc. with effect from 21 May 2025.This announcement is made pursuant to Listing Rule 6.4.9 (2).AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZenecaContactsFor details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.Matthew BowdenCompany SecretaryAstraZeneca PLCThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom

Clinical Trials Arena
May 20th, 2025
ATS 2025: Tozorakimab's safety reinforced with positive results from FRONTIER studies

On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its FRONTIER programmes, which are a series of four Phase II clinical trials.

Cision
May 20th, 2025
Acquisition Of Esobiotec Completed

20 May 2025 Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition (https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html) of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current

INACTIVE